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Abstract
Background: The purpose of this study was to determine peri-operative mortality and long-term out-
comes in patients undergoing liver transplantation in the US using the United Network for Organ Sharing
(UNOS) database.
Methods: This study is a retrospective review of liver transplantations (LT) recorded in the UNOS
database performed between 1988 and 2010. In total, 107 411 LT were performed in the US, 357 (0.3%)
were for adult polycystic liver disease (PLD). A random group of 9416 adult patients transplanted for other
diagnoses was created for comparison (10% of the adult non-PLD database).
Results: Two hundred and seventy-one patients in the adult PLD group were females (75.9%), the mean
age was 52.3  8.2 [standard deviation (SD)] years. The median length of transplantation hospital stay
was 11 days (interquartile range 8–21). Patients from the PLD group versus the comparison group (9416
patients) consisted of more females, lower Model for End-Stage Liver Disease (MELD) scores (17 versus
21 points), more multi-organ transplants (41% versus 4 %), chronic renal failure (creatinine 2.7 versus 1.5)
and fewer patients with chronic hepatitis C (1.4% versus 32%). Peri-operative mortality (30 days) was
9% in the PLD versus 6% in the comparison group; however, at 1 year PLD survival was similar (85%
versus 85%) to other diagnoses and better at 3 (81% versus 77%) and 5 years (77% versus 71%, overall
Log Rank P = 0.006). A similar PLD survival advantage was observed in isolated initial transplants
(P = 0.019).
Conclusion: In spite of early technical challenges and mortality, transplantation should be considered an
option for selected patients with PLD as excellent long-term outcomes can be achieved.
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Introduction
Liver disease affects 5 million people in the United States, of those
around 200 000 have polycystic liver disease (PLD). PLD is an
autosomal dominant disorder that is frequently associated with
polycystic kidney disease (PKD).1–4 PKD is a more aggressive
disease that often progresses to end-stage renal disease, dialysis
and kidney transplantation.3 PLD is characterized by massive
hepatomegaly secondary to numerous diffuse cysts in an other-
wise normal functioning liver.5 Patients with PLD usually have
normal transaminase, alkaline phosphatase and bilirubin concen-
trations. Over 70% of patients are women because the epithelial
lining of the cysts is sensitive to oestrogen.1,4
Patients become clinically symptomatic when the volume of
hepatic cysts increase and patients experience severe abdominal
distention and pain, cyst infections, anorexia, dyspnea and a
decreased quality of life.2–5 Cysts can also cause portal hyperten-
sion, cholangitis, hepatic venous outflow obstruction and inferior
vena cava compression.1
The treatment of choice in asymptomatic cases is observation.
Mild symptoms are common and should be treated conserva-
tively. Patients who have large, painful cysts, portal hypertension
and/or cholangitis are often treated palliatively with cyst decom-
pression done by aspiration or fenestration.1,2,6 A major disadvan-
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tage to those options is that the procedure may have to be repeated
multiple times owing to recurrence. Hepatic resection is an addi-
tional procedure performed to give patients relief of symptoms.2
In some cases orthotopic liver transplantation (OLT) is needed,
especially in advanced cases in which numerous cysts are enlarged,
the quality of life of the patient is markedly diminished and other
significant complications have occurred such as recurrent cholan-
gitis and portal hypertension.2,6
Great controversy surrounds the option of liver transplanta-
tion in PLD patients considering the absence of liver failure, a
critical shortage of organs available and substantial risks of
surgery. In addition, patients receiving liver transplantation
require lifelong monitoring and immunosuppressant medica-
tions.1,3,6 Patients with PLD generally have preserved liver func-
tion and normal Model for End-Stage Liver Disease (MELD)
scores if they do not have renal involvement making transplan-
tation eligibility for these patients difficult. In 2006, Arrazola
et al.7 published in Liver Transplantation guidelines for selection
of patients with PLD including massive disease (total cyst/
parenchyma ratio >1) with complications likely to resolve with
liver transplantation, not candidates for or have disease that
failed to respond to non-transplant interventions, had clinically
significant disease that could be attributed to massive PLD (such
as cachexia, ascites, portal hypertension, cholangitis or recurrent
cyst infections) and severe malnutrition. They proposed that in
the MELD-driven system, eligibility for OLT in PLD patients
should continue to be addressed by the Regional Review Board in
a case-by-case basis. They further proposed that patients could be
given 15 MELD points and MELD could be increased 3 points
every 3 months.
The purpose of this study was to determine peri-operative mor-
tality and long-term outcomes in patients undergoing liver trans-
plantation for PLD in the US using the United Network for Organ
Sharing (UNOS) database.
Methods
The UNOS database was analysed for all patients undergoing
transplantation in the United States from 1988 through to 2010.
Data from adult patients undergoing OLT with a primary diag-
nosis of PLD were captured for analysis. A 10% cohort of patients
transplanted for a diagnosis other than PLD was randomly
selected from the database and used as a comparison group. Data
analysed included recipient age, gender, serum creatinine level,
total bilirubin level, international normalized ratio, coexisting
liver disease, height and weight at the time of transplantation,
blood type, length of hospital stay, number of living versus
deceased donors, incidence of multi-organ transplantations, and
the incidence of acute cellular rejection at 6 months and survival.
The body mass index (BMI) was calculated as weight in kilograms
divided by height in metres squared. Donor characteristics,
including age, cold ischaemia time and fatty infiltration, were also
identified. Paediatric patients were excluded from the analysis.
We compared patient characteristics in the PLD versus the
comparison group using rank, chi-square and t-tests as appropri-
ate. Differences in survival between the two groups were analysed
with the Kaplan–Meier method using the log-rank test in all trans-
plants and in initial isolated transplants only. Multivariable Cox
regression was used to analyse PLD survival versus the compari-
son group with adjustment for age and gender. Survival in patients
undergoing transplantation for PLD with the most common
benign indications for transplantation was also compared: alco-
holic liver disease, primary biliary cirrhosis (PBC) and primary
sclerosing cholangitis (PSC). PLD patients were further divided
into two groups by whether they were transplanted before the year
2000 or later and compared survival by eras. P = 0.05 was consid-
ered significant for all tests. Statistical analysis was performed
using SPSS software, version 10.0.6 (SPSS Inc, Chicago, IL, USA).
Results
Of 107 411 LT liver transplantation procedures in the database,
357 were performed for adult PLD (0.3%). Three-quarters of PLD
patients were female (281/357, 75.9%) and the mean age was 52.3
 8.2 [standard deviation (SD)] years. Approximately one-third
of PLD LT patients were greater than 55 years old (128/357,
34.6%). Patient characteristics in the PLD versus the comparison
group are shown in Table 1. As expected, the group of patients
with a diagnosis of PLD consisted of more females, had lower
MELD scores (16 versus 20 points), received more multi-organ
transplants (42 versus 5 %) and had more chronic renal failure
(mean creatinine levels of 2.8 versus 1.4). They had less liver
dysfunction (demonstrated by less cholestasis) and a higher INR.
The PLD group also had fewer patients with chronic hepatitis C
(1.8% versus 28%) than the comparison group.
Survival analysis
Peri-operative mortality (30 days) was higher in the PLD group
than the comparison group (9% versus 6%) and survival was
lower for the first several months (P < 0.05). However, at 1 year,
PLD survival was similar (85% versus 85%) to other diagnoses
and was better at 3 (81% versus 77%) and 5 years (77% versus
71%, overall log rank P = 0.006). When excluding patients with
multi-organ and repeat transplants, the PLD group (n = 191) had
better survival than the comparison group (n = 8098, log rank P =
0.019) with 1-, 3- and 5-year survival of 88%, 85% and 78% versus
87%, 79% and 73%, respectively (Fig. 1). After adjustment for age
and gender in a multivariable Cox regression analysis of initial
isolated transplant survival, the mortality hazard ratio for PLD
patients relative to other transplants remained protective [hazard
ratio 0.738, 95% confidence interval (CI) 0.550-0.990, P = 0.042].
In comparison with other benign indications, we found that PLD
patients had a survival that was better than alcoholic disease
patients, similar to PBC and worse than PSC (Fig. 2).
Five-year survival improved in PLD patients from 72% in
patients transplanted earlier than the year 2000 to 80% in those
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transplanted in 2000 or later (log rank P = 0.035). In initial iso-
lated transplants between the same periods, the 74% versus the
80% 5-year survival improvement was no longer statistically sig-
nificant (log rank P = 0.381). Peri-operative mortality was 12%
before 2000 versus 7% after year 2000 (P = 0.038, Table 2).
Discussion
Polycystic liver disease is often associated with polycystic kidney
disease and cystic disease in other organs. Recently, a less frequent
form of autosomal dominant of PLD without any associated renal
involvement has been described. Most patients with PLD are
asymptomatic and do not require operative intervention. In more
than 100 000 liver transplant procedures performed during the
study period, only 357 were in patients with a diagnosis of PLD
representing 0.3% of the total of patients captured in the UNOS
dataset. Several authors reported an increased incidence of peri-
operative mortality after transplantation suggesting increased
complexity of the operative procedure and risk for early
complications.1–3 Infectious morbidity was the most common
cause of death but a significant number of patients died from
intra- or early post-operative bleeding. This treatment option is
considered controversial because of the shortage of organs and
multiple complications associated with such an extensive surgery
Table 1 Patient characteristics
Variable Adult PLD
patients
Other adult liver
transplant patients
P-value of
difference
No. of patients 357 9416
Males 86 (24.1%) 5944 (63.1%) <0.001
Recipient age years, mean  SD 52.3  8.2 50.8  10.9 0.001
Recipient age >55 years 128 (35.9%) 3339 (35.5%) 0.879
History malignancy 12 (3.4%) 766 (8.1%) 0.001
Unknown or minority race (24.1%) (23.9%) 0.951
Mean BMI kg/m2  SD 26.3  5.1 27.4  5.8 <0.001
Serum creatinine at transplant 2.7  2.5 1.5  1.3 <0.001
INR at transplant 1.39  1.12 1.84  1.36 <0.001
Cold ischaemic time, mean hours  SD 8.6  5.4 8.3  4.5 0.242
Warm ischaemic time, mean hours  SD 44.7  24.1 49.2  23.6 0.008
MELD score, mean  SD 17.2  8.9 21.2  10.0 <0.001
Transplant hospitalization, median days (interquartile range) 11 (8–21) 12 (8–25) 0.070
Time on the waiting list, median days (interquartile range) 145 (44–434) 79 (17–243) <0.001
Recipient on-dialysis week prior to transplant. 85 (23.8%) 661 (7.0%) <0.001
Positive HCV serostatus 5 (1.4%) 2998 (31.8%) <0.001
Positive hepatitis B surface antigen 2 (0.5%) 524 (4.9%) <0.001
Multi-organ transplant 155 (41.9%) 512 (4.8%) <0.001
Recipient on ventilator 23 (6.2%) 1057 (9.9%) 0.019
History portal vein thrombosis 0 (0%) 222 (2.1%) 0.007
Abdominal surgery prior to transplant 170 (45.9%) 3691 (34.6%) <0.001
BMI, body mass index; INR, International Normalized Ratio; MELD, model for end-stage liver disease; HCV, hepatitis C virus.
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Figure 1 Survival in polycystic liver disease (PLD) versus other liver
transplant patients undergoing isolated, initial liver transplantation
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for a benign disease. However, some patients are at increased risk
of death owing to portal hypertension, recurrent cholangitis and
severe malnutrition.
Recently, van Keimpema et al.8 published the largest retrospec-
tive analysis using the European Liver Transplantation registry
demonstrating excellent long-term survival in patients undergo-
ing transplantation for PLD. They reported a 5-year survival of
87.5% in a series of 58 patients.
Kirchner et al.2 (Hannover, Germany) published the largest
single-center experience in 36 patients with PLD. They reported
an excellent survival of 86% and confirmed that infectious com-
plications are the most common cause of death in PLD patients
after liver transplantation. Cachexia, bleeding from oesophageal
varices and recurrent cyst infection were the most common indi-
cations for OLT. They reported better survival in these patients
undergoing transplantation for PLD than those transplanted for
ALD from the European Registry. A very interesting analysis of
quality of life was performed in this group of 36 patients
transplanted with a diagnosis of PLD and compared with an
age-matched group showing a significant improvement in differ-
ent indicators of quality of life. Cachexia and cyst infection were
found to be predictors of increased peri-operative risk. We were
able to confirm some of their findings showing that patients
undergoing transplantation for PLD have similar survival to those
transplanted for alcoholic liver disease and PBC. In our series,
patients undergoing isolated liver transplantation have similar
outcomes compare to those receiving multi-organ transplants.
Liver transplantation for PLD is technically difficult. The size of
the liver, a previous history of invasive procedures prior to trans-
plant and displacement of the vascular and biliary structures in
the hilum makes the operation technically challenging. We found
that 46% of patients in our series had a history of previous
abdominal surgery which was significantly higher than in patients
transplanted for other causes. We also demonstrated increased
rates of multi-organ transplants in the PLD group as expected.
This could be another explanation for increased peri-operative
mortality and morbidity which supports increased complexity.
Tanner et al. 1 described an increased risk of early post-operative
complications but emphasized the increased risk of intra-
abdominal bleeding requiring re-exploration. Half of the patients
undergoing combined liver and kidney transplantation in this
series had post-operative haemorrhage. A direct relationship was
also found between death and recipient’s age showing that most
patients dying in the early post-operative period were 69 years or
older. This group also recommended early referral and transplan-
tation as malnutrition is usually associated with poor survival.
They also suggested that MELD score exceptions should be con-
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Table 2 Peri-operative mortality before and after 1 January 2000
in polycystic liver disease (PLD) patients and other transplant
diagnoses
30-day mortality
(1-survival)
<1 January
2000
1 January
2000
Wilcoxon's
P-value
PLD 12% (n = 122) 7% (n = 235) 0.038
Other transplants 8% (n = 3520) 5% (n = 5782) <0.001
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sidered in this patient population. Like most single-centre expe-
riences from different groups in the US and Europe, that 5-year
survival of 80% or greater can be possible in these patients was
demonstrated. Furthermore, a significant difference in patient
survival in those transplanted with PLD when compared with a
random group of more than 10 000 patients transplanted for
other diagnoses was shown. It was also demonstrated that patients
transplanted with other diagnoses were associated with a 30%
increase in mortality risk compared with PLD on multivariate
analysis after controlling for age and gender. It is important to
mention that these two groups have different characteristics such
as creatinine, MELD, number of females, prior surgeries, etc. This
makes interpretation of differences in long-term survival difficult.
Surprisingly, 30-day mortality analysis demonstrated that patients
transplanted with PLD had increased peri-operative mortality
even although the group of patients transplanted for other indi-
cations had a significantly higher MELD score and were sicker at
the time of transplant.
Belghiti et al.3 reported 85% 5-year survival rates in patients
undergoing transplantation for PLD. They also showed high
morbidity and peri-operative mortality (15%) in their 27
patients transplanted with PLD. These authors favour liver resec-
tion with or without fenestration initially and suggested that OLT
should be indicated in patients with end-stage renal disease and
malnutrition.
Patients transplanted for PLD had a peri-operative mortality
of 9.5% higher versus 6.5% found in patients transplanted for
other causes different to PLD. This highlights a trend towards
increased 30-day mortality in these patients which could support
the argument of increased complexity. We also separated the
sample in before and after the year 2000 to try to determine
differences in peri-operative mortality by era. We found a signifi-
cant difference in peri-operative mortality by period. Interest-
ingly, 30-day mortality in the PLD group was 7% versus 5% in
the comparison group of patients transplanted for diagnosis dif-
ferent than PLD after the year 2000 (Table 2). This represents a
significant improvement in peri-operative mortality in recent
years for those transplanted for PLD. As expected, more females,
renal failure and multi-organ transplants in patients transplanted
for PLD but less MELD at transplant and rates of hepatitis
C-positive patients were demonstrated.
This is the biggest series of patients transplanted with PLD
which included all the US experience during the study period
using the UNOS dataset. However, this study has several limita-
tions that should be considered. The utilization of a national
database allow data to be collected from a significant number of
patients, nevertheless the database was not created to study this
specific patient population. For that reason there are important
variables that could be of interest that are not captured such us
indication of the transplant procedure, pre-transplant treatments,
pre-transplant imaging used to determine extension of the
disease, operative time, blood product utilization, etc. The
strength of this study comes not only from the large number of
patients included in the database and the possibility to compare a
large number of individuals transplanted with PLD with other
patients undergoing transplantation for other indications during
the same period of time, but also from its clinically robust and
uniform definitions of patient characteristics and events.
In summary, OLT for patients with PLD is associated with
higher peri-operative mortality, significantly more abdominal
surgeries prior and a higher incidence of multi-organ transplants
which could confirm increased complexity. Transplantation
should be considered an option for selected patients with PLD as
excellent long-term outcomes can be achieved. Unfortunately, we
were not able to identify which PLD patients will benefit from
OLT. There is a need for future studies to try to determine and
establish selection criteria for these patients.
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